Danaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Danaher (DHR) reported revenue of $6.05 billion, up 4.4% over the same period last year. EPS came in at $1.89, compared to $1.71 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $6 billion, representing a surprise of +0.94%. The company delivered an EPS surprise of +10.53%, with the consensus EPS estimate being $1.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total Growth - Organic sales (Core): 3% compared to the 2.6% average estimate based on five analysts.Total sales- Diagnostics: $2.46 billion versus $2.39 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.Total sales- Life Sciences: $1.79 billion compared to the $1.81 billion average estimate based on four analysts. The reported number represents a change of +0.6% year over year.Total sales- Biotechnology: $1.8 billion compared to the $1.78 billion average estimate based on four analysts. The reported number represents a change of +8.8% year over year.Operating profit- Life Sciences: $222 million versus the two-analyst average estimate of $165 million.Operating profit- Biotechnology: $352 million compared to the $443.32 million average estimate based on two analysts.Operating profit- Other: $-85 million versus the two-analyst average estimate of $-79.8 million.Operating profit- Diagnostics: $665 million compared to the $546.66 million average estimate based on two analysts.View all Key Company Metrics for Danaher here>>>Shares of Danaher have returned +9.4% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks